• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在根治性外照射放疗后,对头颈部持续性疾病进行组织间近距离放疗。

Interstitial brachytherapy in the management of persistent head and neck disease after definitive external beam radiation therapy.

作者信息

Grimard Laval, Esche Bernd, Lamothe André, Spaans Johanna N

机构信息

Department of Radiation Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.

出版信息

Brachytherapy. 2009 Jul-Sep;8(3):284-9. doi: 10.1016/j.brachy.2008.12.007. Epub 2009 May 15.

DOI:10.1016/j.brachy.2008.12.007
PMID:19446500
Abstract

PURPOSE

Persistent disease after definitive external beam radiation therapy for head and neck (H&N) malignancies negatively impacts survival. In this series, the effectiveness of low-dose-rate brachytherapy in the management of persistent H&N disease is explored.

METHODS

All patients who received brachytherapy for persistent H&N disease between 1987 and 2002 were identified. Tumor and treatment characteristics and toxicities were recorded. Progression-free survival and overall survival estimates were generated. The influence of prognostic factors was determined.

RESULTS

Twelve patients were analyzable. Brachytherapy was given curatively (n=4) in patients not amenable to surgery or in combination with surgical dissection to avoid carotid resection (n=8). Seven patients had disease progression with a median time to progression of 11 months (95% confidence interval: 0-22.9). The only negative prognostic factor was time to re-treatment (brachytherapy >4 months) after definitive treatment (p=0.003). Overall survival at 1 and 5 years was 50% and 21%, respectively. Toxicity was limited to one major complication (fistula) and five minor toxicities: low-grade radionecrosis (n=2), cellulitis (n=1), and wound dehiscence (n=2).

CONCLUSION

In patients with persistent disease, brachytherapy is an appealing re-treatment alternative. When combined with neck dissection, brachytherapy yields less morbidity than the surgical alternative of carotid resection.

摘要

目的

头颈部(H&N)恶性肿瘤在接受确定性外照射放疗后出现持续性疾病会对生存产生负面影响。在本系列研究中,探讨了低剂量率近距离放疗在治疗持续性H&N疾病中的有效性。

方法

确定了1987年至2002年间所有因持续性H&N疾病接受近距离放疗的患者。记录肿瘤和治疗特征及毒性反应。生成无进展生存期和总生存期估计值。确定预后因素的影响。

结果

12例患者可进行分析。对于不宜手术的患者(n = 4)或为避免颈动脉切除而与手术切除联合进行近距离放疗(n = 8)。7例患者出现疾病进展,中位进展时间为11个月(95%置信区间:0 - 22.9)。唯一的负面预后因素是确定性治疗后再次治疗的时间(近距离放疗>4个月)(p = 0.003)。1年和5年的总生存率分别为50%和21%。毒性反应仅限于1例主要并发症(瘘管)和5例轻微毒性反应:低度放射性坏死(n = 2)、蜂窝织炎(n = 1)和伤口裂开(n = 2)。

结论

对于患有持续性疾病的患者,近距离放疗是一种有吸引力的再次治疗选择。与颈部清扫术联合使用时,近距离放疗产生的发病率低于颈动脉切除的手术替代方案。

相似文献

1
Interstitial brachytherapy in the management of persistent head and neck disease after definitive external beam radiation therapy.在根治性外照射放疗后,对头颈部持续性疾病进行组织间近距离放疗。
Brachytherapy. 2009 Jul-Sep;8(3):284-9. doi: 10.1016/j.brachy.2008.12.007. Epub 2009 May 15.
2
Interstitial low-dose-rate brachytherapy in the treatment of recurrent head and neck malignancies.间质低剂量率近距离放射疗法治疗复发性头颈部恶性肿瘤
Head Neck. 2006 Oct;28(10):888-95. doi: 10.1002/hed.20422.
3
High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.高剂量率组织间近距离放射治疗复发性及既往接受过放疗的头颈癌——初步结果
Brachytherapy. 2007 Apr-Jun;6(2):157-63. doi: 10.1016/j.brachy.2006.12.001.
4
High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer.高剂量率近距离放射治疗复发性和残留性头颈癌
Laryngoscope. 2002 Aug;112(8 Pt 1):1366-71. doi: 10.1097/00005537-200208000-00008.
5
Interstitial high-dose-rate brachytherapy combined with cervical dissection on head and neck cancer.间质高剂量率近距离放射疗法联合颈清扫术治疗头颈癌
Head Neck. 2005 Dec;27(12):1035-41. doi: 10.1002/hed.20278.
6
The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers.间质近距离放疗联合挽救性手术在复发性头颈癌治疗中的作用。
Cancer. 2007 May 15;109(10):2052-7. doi: 10.1002/cncr.22648.
7
Perioperative high-dose-rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Initial results of a Phase I/II reirradiation study.既往接受过放疗的头颈部癌围手术期高剂量率近距离放疗(PHDRB):一项I/II期再放疗研究的初步结果
Brachytherapy. 2006 Jan-Mar;5(1):32-40. doi: 10.1016/j.brachy.2005.11.003.
8
High-dose-rate brachytherapy plus neck dissection for nodal disease.高剂量率近距离放射治疗联合颈部淋巴结清扫术治疗淋巴结疾病。
Head Neck. 2008 Jul;30(7):933-8. doi: 10.1002/hed.20799.
9
Exclusive brachytherapy for T1 and T2 squamous cell carcinomas of the velotonsillar area: results in 44 patients.
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):441-8. doi: 10.1016/j.ijrobp.2005.02.002.
10
Combination of surgical resection and HDR-brachytherapy in patients with recurrent or advanced head and neck carcinomas.复发性或晚期头颈癌患者手术切除与高剂量率近距离放射治疗的联合应用。
J Craniomaxillofac Surg. 2008 Jul;36(5):285-92. doi: 10.1016/j.jcms.2007.08.009. Epub 2008 Mar 18.

引用本文的文献

1
Intensity modulated perioperative HDR brachytherapy for recurrent and/or advanced head and neck metastases.调强围手术期高剂量率近距离放射治疗复发性和/或晚期头颈部转移瘤。
Eur Arch Otorhinolaryngol. 2016 Sep;273(9):2707-15. doi: 10.1007/s00405-015-3794-3. Epub 2015 Oct 23.
2
Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.现代头颈部近距离放射治疗:从镭到调强介入性近距离放射治疗。
J Contemp Brachytherapy. 2015 Jan;6(4):404-16. doi: 10.5114/jcb.2014.47813. Epub 2014 Dec 31.
3
Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: Long-term results.
复发性头颈癌采用挽救性组织间脉冲剂量率近距离放射治疗的再照射:长期结果。
Strahlenther Onkol. 2015 Jun;191(6):495-500. doi: 10.1007/s00066-014-0809-8. Epub 2015 Jan 10.
4
The role of brachytherapy in the treatment of squamous cell carcinoma of the head and neck.近距离放射治疗在头颈部鳞状细胞癌治疗中的作用。
Eur Arch Otorhinolaryngol. 2016 Feb;273(2):269-76. doi: 10.1007/s00405-014-3332-8. Epub 2014 Oct 22.
5
Oral cancer: Current role of radiotherapy and chemotherapy.口腔癌:放疗和化疗的当前作用。
Med Oral Patol Oral Cir Bucal. 2013 Mar 1;18(2):e233-40. doi: 10.4317/medoral.18772.